POST-TEST

Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3and IDH1/2-Mutant Acute Myeloid Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III QuANTUM-First trial evaluating quizartinib or placebo in combination with chemotherapy as induction and consolidation therapy, followed by quizartinib or placebo, for patients with newly diagnosed FLT3-ITD acute myeloid leukemia (AML) demonstrated which clinical outcome on the quizartinib arm?
 - a. Improvement in overall survival in patients with NPM1-mutated AML only
 - Improvement in overall survival in patients with DNMT3A-mutated AML only
 - c. Improvement in overall survival in patients with NPM1- or DNMT3A-mutated AMI
- 2. Interim results of the Phase II QUIWI trial comparing standard chemotherapy with quizartinib to standard chemotherapy with placebo suggest that the addition of quizartinib may prolong overall survival in which of the following settings?
 - a. Newly diagnosed FLT3-ITD wild-type AML
 - b. Newly diagnosed FLT3-ITD-mutated AMI
 - c. Relapsed/refractory FLT3-ITD wild-type AML
 - d. Relapsed/refractory FLT3-ITDmutated AML

- 3. Which of the following statements best describes the efficacy of post-transplant maintenance gilteritinib compared to placebo, reported by minimal residual disease (MRD) status in the Phase III MORPHO study for patients with FLT3-ITD AML?
 - a. Gilteritinib improved survival for only those patients with high MRD detection
 - b. Gilteritinib improved survival for only those patients with undetectable MRD
 - c. Gilteritinib improved survival for all patients regardless of MRD status
- 4. Olutasidenib has demonstrated activity in which category of AML?
 - a. FLT3-ITD-mutant AMI
 - b. FLT3-TKD-mutant AML
 - c. IDH1-mutant AML
- 5. Ten-year follow-up of the RATIFY trial of standard chemotherapy with midostaurin or placebo demonstrated which outcome with midostaurin combined with chemotherapy for newly diagnosed FLT3-mutated AML?
 - a. A median overall survival of approximately 21 months
 - b. A median overall survival of approximately 43 months
 - c. A median overall survival of approximately 75 months